Market Analysis 

Injectable drug delivery, simply put, is the delivery of pharmaceutical compounds, medicines, or drugs into the body through the bloodstream for therapeutic effects. This is the most common and effective route to administer most therapeutic agents for a quick response.

The injectable drug delivery devices market is anticipated to touch USD 31,900 million at an 11.5% CAGR between 2018-2023, states the latest Market Research Future (MRFR) report 

Market Segmentation

The MRFR report provides an all-inclusive segmental analysis of the injectable drug delivery devices market on the basis of the facility of use, distribution channel, site of delivery, usage pattern, therapeutic application, and devices. 

By devices, the global injectable drug delivery devices market is segmented into self-injection devices and conventional injection devices. Of these, the conventional injection devices segment will lead the market during the forecast period.

By therapeutic application, the global injectable drug delivery devices market is segmented into cancer, hormonal disorders, autoimmune diseases, and others. Of these, the autoimmune diseases segment will dominate the market during the forecast period.

By usage pattern, the global injectable drug delivery devices market is segmented into immunization and curative. Of these, the curative segment will have the largest share in the market during the forecast period.

By distribution channel, the global injectable drug delivery devices market is segmented into online platforms and hospital and retail pharmacies. Of these, the hospitals and retail pharmacies will dominate the market during the forecast period.

Regional Analysis

By region, the injectable drug delivery devices market report covers the latest trends and growth opportunities across the Asia Pacific, the Middle East and Africa, Europe, and the Americas. Of these, the Americas will spearhead the market during the forecast period. Factors propelling the growth of the injectable drug delivery devices market in the region include the presence of an established healthcare sector, increased incidence of chronic diseases, booming biotechnological industry, and rapid adoption of technologically advanced healthcare solutions.

The injectable drug delivery devices market in Europe will have the second-largest share in the market during the forecast period. Factors propelling the growth of the injectable drug delivery devices market in the region include increased RD funding coupled with the easy and rapid adoption of healthcare services that are technologically advanced.

The worldwide injectable drug delivery devices market in the APAC region will have a favorable growth during the forecast period, mainly for the burgeoning demand for therapeutics in the expanding healthcare industry in the region’s developing economies.

The global injectable drug delivery devices market in the MEA will have a steady growth during the forecast period for less exposure to primary healthcare services and a lack of awareness. 

Key Players

Notable players profiled in the injectable drug delivery devices market report include Inovio Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Sanofi, Pfizer Inc., Novo Nordisk, Novartis AG, Mylan N.V., Johnson Johnson Services Inc., Dickinson and Company, Becton, F.Hoffmann-La Roche AG, Eli Lilly and Company, AstraZeneca, Antares Pharma, and Eisai Co. Ltd.